Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | Phase 2 | terminated | Oct 3, 2012 | Greg Monohan | Research cancelled following interim analysis | Efficacy / futility |
| NCT00788606 | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma | Phase 2 | terminated | Nov 11, 2008 | Royal Marsden NHS Foundation Trust | Toxicity and efficacy data from another trial | Safety / toxicity |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple… | Phase 1 | terminated | Jun 3, 2009 | Cougar Biotechnology, Inc. | Terminated early due to lack of clinical response. | Other (stated, no rule matched) |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in… | Phase 1 / Phase 2 | withdrawn | Nov 16, 2015 | Bayer | Study restarted under new study number 18987 | Other (stated, no rule matched) |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | N/A | terminated | Aug 26, 2011 | Merck KGaA, Darmstadt, Germany | The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide… | Sponsor / business decision |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT00416910 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic… | Phase 3 | terminated | Dec 28, 2006 | German CLL Study Group | low recruitment | Enrollment / accrual |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | Phase 2 | terminated | Oct 12, 2015 | Henrik Gregersen | Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide… | Other (stated, no rule matched) |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 | terminated | Nov 15, 2013 | M.D. Anderson Cancer Center | Terminated Phase I due to slow accrual without progression to Phase II. | Enrollment / accrual |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone… | Phase 2 | terminated | May 12, 2010 | Duke University | The study closed temporarily in February 2012 pending analysis of samples collected. In October,… | Other (stated, no rule matched) |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in… | Phase 2 / Phase 3 | terminated | Sep 25, 2009 | Shanghai Jiao Tong University School of Medicine | Very slow recruitment | Enrollment / accrual |
| NCT02230917 | A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple… | Phase 2 | withdrawn | Sep 3, 2014 | Rebecca Silbermann | not stated | Not stated |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | Phase 2 | terminated | Oct 10, 2008 | Northwell Health | study suspended while data is reviewed for safety and efficacy. | Safety / toxicity |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic… | Phase 1 | withdrawn | Dec 29, 2015 | AbbVie | Study Stopped | Other (stated, no rule matched) |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | Phase 1 | terminated | Mar 2, 2010 | Steven P. Treon, MD, PhD | Safety concerns (IgM Flare) | Safety / toxicity |
| NCT01096810 | Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma | Phase 2 | terminated | Mar 31, 2010 | Jagannath, Sundar, M.D. | The research is permanently closed to enrollment. | Enrollment / accrual |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | Phase 3 | terminated | Apr 15, 2016 | Hoffmann-La Roche | Slow recruitment | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Jan 28, 2014 | Ångstrom Pharmaceuticals | Slow enrollment | Enrollment / accrual |
| NCT02447055 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | Early Phase 1 | withdrawn | May 18, 2015 | Washington University School of Medicine | not stated | Not stated |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | Phase 2 | terminated | Sep 24, 2009 | University of Utah | Lab Staff that was required left the institution, therefore accrual closed prematurely | Enrollment / accrual |
| NCT01649791 | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell… | N/A | terminated | Jul 25, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic…(NADIR) | — | terminated | Oct 24, 2014 | Astellas Pharma International B.V. | The study was terminated due to insufficient subject enrollment and very slow enrollment. | Enrollment / accrual |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
| NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia…(Rev-CLL) | Phase 2 | terminated | Sep 11, 2008 | University Health Network, Toronto | Seven years of follow-up \& final analysis done in Dec 2012. | Other (stated, no rule matched) |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom… | Phase 2 | terminated | Feb 20, 2012 | Roswell Park Cancer Institute | funding was withdrawn | Funding |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | Phase 1 / Phase 2 | terminated | Aug 7, 2012 | National Cancer Institute (NCI) | study closed prematurely because investigator left National Institutes of Health | Investigator |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | Phase 1 | terminated | Oct 12, 2007 | Dana-Farber Cancer Institute | lack of efficacy and tolerability | Efficacy / futility |
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic… | Phase 1 | terminated | Aug 16, 2010 | University of Rochester | low enrollment | Enrollment / accrual |
| NCT01807286 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | Phase 1 | terminated | Mar 8, 2013 | M.D. Anderson Cancer Center | Sponsor requested termination | Other (stated, no rule matched) |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus… | Phase 3 | withdrawn | Apr 13, 2016 | Acerta Pharma BV | not stated | Not stated |
| NCT00892346 | Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line… | Phase 3 | suspended | May 4, 2009 | Shanghai Jiao Tong University School of Medicine | No avaliability of melphlan in mainland China | Other (stated, no rule matched) |
| NCT01501370 | Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in…(ZLd_Ld) | Phase 2 | withdrawn | Dec 29, 2011 | Tiziana Marangon | not stated | Not stated |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT01016028 | Chemotherapy-Induced Peripheral Neuropathy Survey | — | withdrawn | Nov 18, 2009 | M.D. Anderson Cancer Center | Study assessment tool development delayed. | Other (stated, no rule matched) |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Sep 2, 2005 | Dana-Farber Cancer Institute | Toxicity | Safety / toxicity |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | Phase 2 | terminated | Apr 16, 2012 | Samsung Medical Center | we collected data of a total of 19 patients for an interim analysis. but there are less than 7… | Efficacy / futility |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of… | Phase 1 / Phase 2 | terminated | Dec 2, 2009 | Cephalon | not stated | Not stated |
| NCT02140840 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the… | Phase 2 | withdrawn | May 16, 2014 | University of Arkansas | PI left institution | Investigator |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity… | Phase 2 | terminated | Feb 14, 2008 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | Phase 2 | terminated | Jan 25, 2012 | M.D. Anderson Cancer Center | Objectives not met. | Other (stated, no rule matched) |
| NCT00836173 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate,… | Phase 2 | withdrawn | Feb 4, 2009 | Loyola University | Gallium is no longer available for the conduct of this study. | Other (stated, no rule matched) |
| NCT02556346 | Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose… | Phase 1 | withdrawn | Sep 22, 2015 | Molecular Templates, Inc. | The patient population (CLL \& SLL) was included in another ongoing study involving NHL patients. | Other (stated, no rule matched) |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL(ASPIRE) | Phase 3 | withdrawn | Feb 4, 2014 | Asan Medical Center | No consensus among trial centers regarding protocol | Other (stated, no rule matched) |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | Phase 2 | terminated | Jun 15, 2006 | Asan Medical Center | poor accrual and response less than expected on interim analysis | Efficacy / futility |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma…(VEIL) | Phase 2 | terminated | Dec 28, 2011 | Peter MacCallum Cancer Centre, Australia | Poor recruitment rate | Enrollment / accrual |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2011 | University of Pittsburgh | Clinical trial being transferred to Columbia University with the Investigator. | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 18, 2016source: clinicaltrials